



# Arrhythmogenic Cardiomyopathy



**Petros Nihoyannopoulos, MD, FRCP**  
**Professor of Cardiology**  
**Imperial College London**  
**Hammersmith Hospital, NHLI**



# Cardiomyopathies

**HCM**    **DCM**    **ARVC**    **RCM**    **Unclassified**



**Familial /  
Genetic**

**Non-Familial /  
Non-Genetic**

**Unidentified  
gene defect**


**Disease  
sub-type**

**Idiopathic**

**Disease  
sub-type**

# Sudden Cardiac Death

## ARVC



- Inherited cardiomyopathy characterized by fibro-fatty myocardial replacement, ventricular arrhythmia, RV dysfunction and sudden cardiac death
- Genetically determined 1:1000
- Autosomal dominant with incomplete penetrance (genes which encode desmosomal proteins)
- Recessive variants have been described, often associated with skin disorders and woolly hair

# ARVC or arrhythmogenic cardiomyopathy?

The LV is so frequently involved as to support the adoption of the broad term “arrhythmogenic cardiomyopathy”

Basso C et al. Lancet 2009;373:1289-1300

- **Classic** (isolated RV disease or LV involvement after notable RV disease)
- **Left dominant** (prominent LV involvement, relatively mild RV-sided disease)
- **Biventricular** (equal bilateral involvement)



# Population to Target

- Young middle-aged patients with symptoms of arrhythmia (palpitation, pre-syncope or syncope, CP, SOB)
- Survivors of VF arrest
- 1st/2nd-degree relatives of SCD with pathologically proven ARVC
- Relatives of index cases with a clinical diagnosis of ARVC
- Relatives of SCD victims with “negative” post-mortem - ARVC may be missed on autopsy! - retain tissue for expert cardiac pathologist!
- Patients with isolated RHF in the absence of PHT
- Patients with apparent DCM but predominantly arrhythmic manifestations - FHx of SCD



# Diagnosis

- Difficult
- No single test to establish or exclude diagnosis
- Based on a constellation of clinical, ECG, Echo and other features
- Important to make the correct diagnosis
- Imaging of questionable use in early disease, few cell can be substrate for fatal arrhythmia
- Dilated RV non-specific

# A single test is seldom sufficient to establish a clinical diagnosis of ARVC

- Full History
- Detail pedigree (SCD)
- ECG (ICD, iRBBB, RBBB, inverted T-waves V1-3)
- Signal-average ECG for late potentials
- 2DE ± contrast (by experienced operators)
- ETT for ventricular arrhythmia
- Ambulatory monitoring
- cMR (by an experienced operator)  
(fibro-fatty replacement not discernible by imaging)



# Criteria for diagnosis of ARVC

## Original Task Force Criteria

*McKenna WJ, et al. Br Heart J 1994;71:215-18*

### 1. Global or regional dysfunction and structural alterations

#### MAJOR

- Severe dilatation and reduction of RV function with no LV impairment (only mild)
- Localised RV aneurysms (akinetic or dyskinetic areas with diastolic bulging)
- Severe segmental dilatation of the RV

#### MINOR

- Mild global RV dilatation or reduced ejection fraction with normal LV
- Mild segmental dilatation of the RV
- Regional RV hypokinesia.

### 2. Tissue characterization of walls

#### MAJOR

Fibrofatty replacement of myocardium on endomyocardial biopsy

### 3. Repolarisation abnormalities

#### MINOR

Inverted T waves in right precordial leads (V2 and V3) in people aged more than 12 yrs in absence of RBBB).

# Criteria for diagnosis of ARVC


## 4. Depolarisation/Conduction abnormalities

### MAJOR

Epsilon waves or localized prolongation (>110 msec) of the QRS complex  
In right precordial leads (V1 to V3).

### MINOR

Late potentials (signal averaged ECG)



## 5. Arrhythmia

### MINOR

- LBBB type ventricular tachycardia (sustained and non-sustained)
- Frequent ventricular extrasystoles (more than 1000/24h) on Holter

## 6. Family history


### MAJOR

Familial disease confirmed at necropsy or surgery

### MINOR

- Familial history of premature sudden death (<35yrs) due to suspected RV dysplasia.
- Familial history (clinical diagnosis based on present criteria)

# Diffuse Non-epidermolytic Palmoplantar Keratoderma and Woolly Hair (Naxos Disease) Maps to 17q21




- Population: 12,089
- Area: 126.957 km<sup>2</sup> (49 sq mi)
- Density: 95 /km<sup>2</sup> (247 /sq mi)



Palmar  
plantar keratoderma  
**Locus 17q21**

Coonar AS, Protonotarios N, Tsatsopoulou A, Needham EWA,  
Houlston RS, Cliff S, Otter MI, Murday VA, Mattu RK, McKenna WJ.  
Circulation, 1998;97:2049 - 2058

# The cardiac desmosome



- ▶ desmocollin
- ▶ desmoglein
- ▶ desmoplakin
- ▶ plakoglobin
- ▶ plakophilin

- Support structural stability: cell-cell adhesion
- Regulate gene transcription for adipogenesis, apoptosis
- Maintain electrical conductivity through gap junctions and  $\text{Ca}^{++}$  homeostasis



# Diagnosis of ARVC/D

## Genetic Heterogeneity

ARVD1	AD	(14q23-q24)	TGF b3
ARVD2	AD	(1q42-q43)	RyR2 - idiopathic VT
ARVD3	AD	(14q12-q22)	?
ARVD4	AD	(2q32.1-q32.3)	?
ARVD5	AD	(3q23)	TMEM 43
ARVD6	AD	(10p12-p14)	?
ARVD7	AD	(10q22)	?
Naxos Disease	AR	(17q21)	JUP (plakoglobin)
ARVD8	AD	(6p24)	DSP (desmoplakin)
ARVD9	AD	(12p11)	PKP-2 (plakophilin)
ARVD10	AD	(18q12.1)	DSG-2 (desmplein)
ARVD11	AD	(18q12.1)	DSC-2 (desmocollin)
ARVD12	AD	(17q21)	JUP
Carvajal Syndrome	AR	(6p24)	DSP

# Diagnosis of ARVC cannot be made by a single test

## Original Task Force Criteria

McKenna WJ, et al. *Br Heart J* 1994;71:215-18

*highly specific*

*lack of sensitivity*

## Proposed Modifications

Marcus F, McKenna WJ, et al. *Circulation*;121(13),2010,1533-41

- Global or regional dysfunction and structural alterations
- Tissue characterisation of walls
- Repolarisation abnormalities
- Depolarisation/conduction abnormalities
- Arrhythmias
- Family history

*Each group includes major and minor criteria*

# Global or regional dysfunction or structural alterations

## Original Task Force Criteria

### Major

- Severe dilatation & reduction of RV EF with no or mild LV involvement
- Localised RV aneurysms (akinetic or dyskinetic areas with diastolic bulging)
- Severe segmental RV dilatation

### Minor

- Mild global RV dilatation and/or reduced EF with normal LV
- Mild segmental RV dilatation
- Regional RV hypokinesia

## Modified Task Force Criteria

### Major (by 2D Echo)

- Regional RV akinesia, dyskinesia or aneurysm **and** 1 of the following:
  - PLAX RVOT  $\geq 32\text{mm}$  ( $\geq 19\text{mm/m}^2$ )
  - PSAX RVOT  $\geq 36\text{mm}$  ( $\geq 21\text{mm/m}^2$ )
  - or Fractional Area Change  $\leq 33\%$

### Minor (By 2D Echo)

- Regional RV akinesia, dyskinesia or aneurysm and 1 of the following:
  - PLAX RVOT  $\geq 29 < 32\text{mm}$  ( $\geq 16\text{mm/m}^2 - 19\text{mm/m}^2$ )
  - PSAX RVOT  $\geq 32 < 36\text{mm}$  ( $\geq 18\text{mm/m}^2 - 21\text{mm/m}^2$ )
  - or FAC  $> 33\% \leq 40\%$

# Global or regional dysfunction or structural alterations

## Original Task Force Criteria

### Major

- Severe dilatation & reduction of RV EF with no or mild LV involvement
- Localised RV aneurysms (akinetic or dyskinetic areas with diastolic bulging)
- Severe segmental RV dilatation

### Minor

- Mild global RV dilatation and/or reduced EF with normal LV
- Mild segmental RV dilatation
- Regional RV hypokinesia

## Modified Task Force Criteria

### Major (by CMR)

- Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
- and 1 of the following:
  - Ratio of RV end-diastolic volume to BSA  $\geq 110 \text{ mL/m}^2$  (M) or  $\geq 100 \text{ mL/m}^2$  (F)
  - or RV EF  $< 40\%$

### Minor (by CMR)

- Regional RV akinesia, dyskinesia or dyssynchronous RV contraction
- and 1 of the following:
  - Ratio of RV end-diastolic volume to BSA  $\geq 100$  to  $< 110 \text{ mL/m}^2$  (M)
  - or  $\geq 90$  to  $< 100 \text{ mL/m}^2$  (F)
  - or RV EF  $\geq 40\%$   $< 45\%$

# Modified Task Force Criteria

## ● Repolarisation abnormalities

### Major

TWI in right precordial leads (V1, V2 & V3) or beyond in individuals >14y (in the absence of RBBB)

### Minor

TWI in leads V1, V2 in individuals >14y or in V4, V5 or V6 (in the absence of RBBB)

Inverted T-waves in leads V1, V2, V3 V4 in individuals >14y

## ● Depolarisation / conduction abnormalities

### Major

Epsilon wave in V1-V3






### Minor

Late potentials by SAECG in >1 or 3 parameters in the absence of  $QRS \geq 110\text{ms}$

Terminal activation duration of QRS 55ms (nadir of the S-wave to the end of QRS) in V1-3



# ECG with typical signs for ARVC: Negative T-waves and epsilon waves





# Modified Task Force Criteria

## Tissue characterisation of wall

### Major

- Residual myocytes  $<60\%$  by morphometric analysis (or  $<50\%$  if estimate), **with fibrous replacement of the RV free wall** in  $\geq 1$  sample, with or without fatty replacement of tissue on endomyocardial biopsy

### Minor

- Residual myocytes  $60\%-75\%$  by morphometric analysis (or  $50\%-65\%$  if estimated), **with fibrous replacement of the RV free wall** in  $\geq 1$  sample

## Arrhythmias

### Major

- NSVT or sustained VT of LBBB morphology with superior axis (negative or indeterminate QRS in II, III, aVF and positive in aVL)

### Minor

- NSVT or sustained VT of LBBB morphology with inferior axis (positive in II, III, aVF and negative in aVL)
- 500 ventricular extrasystoles / 24h (Holter)



# Modified Task Force Criteria

## Family History

### Major

- ARVC confirmed in a first-degree relative who meets current Task Force criteria
- ARVC confirmed at autopsy or surgery in a first-degree relative
- Identification of a pathogenic mutation categorised as associated or probably associated with ARVC in the patient under evaluation

### Minor

- History of ARVC in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current criteria
- Premature SD (<35y) due to suspected ARVC in a first-degree relative
- ARVC confirmed pathologically or by current Task Force Criteria



# Organization of family screening

Patient with unequivocal cardiomyopathy (proband)

Genetic testing

Not performed  
or no mutation was identified

A mutation is identified

Cardiac screening (ECG + Echo)\*  
in (first-degree) relatives

Predictive genetic testing  
in (first-degree) relatives

A CMP is diagnosed

No CMP

Mutation is present

No mutation

–Complete cardiac examination  
and regular FU  
–Propose cardiac screening  
to offspring  
(cascade strategy)

–Continue regular  
cardiac FU  
(possible delayed  
expression)

–Complete cardiac examination  
and regular FU  
–Propose genetic screening  
to offspring  
(cascade strategy)

–Stop examination  
and no FU  
–No screening  
to offspring




# Revised Task Force Criteria

<b>Definite</b>	<b>Borderline</b>	<b>Possible</b>
<b>2 major</b>	<b>1 major + 1 minor</b>	<b>1 major</b>
<b>1 major + 2 minor</b>	<b>3 minor</b>	<b>2 minor</b>
<b>4 minor</b>		





# Triangle of Dysplasia







Map 3  
170dB/C 3  
Persist Low  
2D Opt:HGen  
Fr Rate:High  
BW 0 Pg 0  
Col 0 Pg 0




BW 0 Pg 0  
Col 0 Pg 0








Map 3  
170dB/C 3  
Persist Low  
2D Opt: HGen  
Fr Rate: High  
BW 0 Pg 0  
Col 0 Pg 0





BW 0 Pg 0  
Col 0 Pg 0






# ?? RV Dysfunction





# RV speckle Tracking



**ARVC**




# Apical 4-Chamber



HOSPITAL P4-2 A.Card/Gen 3:18:30 pm 72 Hz 14.4cm

Map 1  
170dB/C 3  
Persist Low  
2D Opt:HGen  
Fr Rate:High  
BW 0 Pg 0  
Col 0 Pg 0



HAMMERSMITH HOSPITAL P4-2 A.Card/Gen 10:28:36 am 80 Hz 12.7cm

Map 3  
170dB/C 3  
Persist Low  
2D Opt:HGen  
Fr Rate:High  
BW 0 Pg 0  
Col 0 Pg 0



HOSPITAL P4-2 A.Card/Gen 10:44:20 98 Hz 10.0cm

Map 1  
170dB/C 3  
Persist Low  
2D Opt:HGen  
Fr Rate:High  
BW 0 Pg 0  
Col 0 Pg 0



HAMMERSMITH HOSPITAL P4-2 A.Card/Gen 10:44:20 98 Hz 10.0cm

Map 3  
170dB/C 3  
Persist Low  
2D Opt:HGen  
Fr Rate:High  
BW 0 Pg 0  
Col 0 Pg 0



# Natural History



## Subclinical Phase

No symptoms  
Subtle ECG changes  
No structural abnormalities  
SD can occur

## Overt RV electrical phase

Palpitations, syncope, SD  
VE, VT, VF  
Structural changes detected

## RV failure phase




HF symptoms  
VE, VT, VF, SD  
RV dilatation-dysfunction

## End-stage phase

Biventricular involvement  
Severe HF symptoms  
Transplantation, death

# Cardiac Magnetic Resonance Imaging

- 1.5 or 3T scanners
- Dedicated phased-array coils with multiple elements
- ECG triggering
- Expert centres
- **Functional:** Dilatation, global/regional function, focal aneurysms (subjective), RV volumes, EF
- **Morphological:** Focal thinning, RVOT enlargement, fatty infiltration with T1 weighted spin echo images (not a task force criterion)
- **Delayed enhancement:** Detection of fibrosis ??prognostic implications not defined  
LV involvement





# Summary

- ARVC has a wide spectrum of manifestations
- Electrical abnormalities predominate in early stages
- Overt structural alterations develop progressively
  
- Diagnosis cannot be made by a single test
- Task Force Criteria have to be implemented to obtain diagnosis
  
- ARVC is not only a RV disease
- Frequent LV involvement also occurs (arrhythmogenic cardiomyopathy)
  
- Echocardiography remains the first choice imaging technique for ARVC
- CMR offers invaluable diagnostic and prognostic assistance



Thank You!

[petros@imperial.ac.uk](mailto:petros@imperial.ac.uk)